The FDA and the State of Chronic Diseases: Cardiovascular, Endocrine, Pulmonary, and Renal Diseases

Abstract excerpt

Despite needs for new therapies and improvements in existing approaches in cardiovascular, pulmonary, endocrine, and renal disease, investment in these areas is lagging relative to other specialties. This article summarizes a meeting of key stakeholders of U.S. Food and Drug Administration (FDA) officials, representatives from academia, national organizations, and patients and caregivers. The purpose was to identi...

Topics

Open a Topic to create a Post that cites this publication.

• Adrenergic beta-Agonists
• Adrenergic beta-Antagonists
• Costs and Cost Analysis
• Early Diagnosis
• Echocardiography
• Genetic Associations and Epidemiology
• Practice Guidelines as Topic
• Randomized Controlled Trials as Topic

Identifiers and source

Literature Corpus work

d5db2aa0-3590-5114-9b32-b926d4aac2b7

DOI

10.20944/preprints201805.0050.v1